Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)

Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas Short, Rita Khouri, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Ghayas Issa, Vicki Jeanis, Gal Moore, Rebecca Garris, Naveen Pemmaraju, Jorge Cortes, Susan O'Brien, Hagop Kantarjian

Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research